| Investor | Cormorant Asset Management, LP |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Cormorant Asset Management, LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | 13G | RLYB / Rallybio Corporation | 400,000 | |||||
| 2026-05-15 | 13G/A | RAPP / Rapport Therapeutics, Inc. | 3,027,521 | 2,957,521 | ||||
| 2026-05-15 | 13G/A | MLTX / MoonLake Immunotherapeutics | 4,355,433 | 4,480,433 | ||||
| 2026-05-15 | 13G/A | IBIO / iBio, Inc. | 2,248,010 | 3,834,335 | ||||
| 2026-05-15 | 13G/A | CABA / Cabaletta Bio, Inc. | 9,400,000 | 10,500,000 | ||||
| 2026-05-15 | 13G/A | BIOA / BioAge Labs, Inc. | 2,040,605 | 2,890,605 | ||||
| 2026-05-15 | 13G | ANL / Adlai Nortye Ltd. - Depositary Receipt (Common Stock) | 2,897,857 | |||||
| 2026-05-15 | 13G | AGMB / AgomAb Therapeutics NV - Depositary Receipt (Common Stock) | 2,465,348 | |||||
| 2026-05-15 | 13G/A | ENGN / enGene Therapeutics Inc. | 4,000,000 | 0 | ||||
| 2026-04-30 | 13G/A | DRUG / Bright Minds Biosciences Inc. | 950,000 | |||||
| 2026-02-17 | 13G/A | BIOA / BioAge Labs, Inc. | 2,140,605 | 2,040,605 | ||||
| 2026-02-17 | 13G/A | RAPP / Rapport Therapeutics, Inc. | 3,192,521 | 3,027,521 | ||||
| 2026-02-17 | 13G | ENGN / enGene Therapeutics Inc. | 4,000,000 | |||||
| 2026-02-17 | 13G | MLTX / MoonLake Immunotherapeutics | 4,355,433 | |||||
| 2026-02-17 | 13G/A | CABA / Cabaletta Bio, Inc. | 9,591,983 | 9,400,000 | ||||
| 2026-02-06 | 13G/A | DRUG / Bright Minds Biosciences Inc. | 1,059,331 | 1,059,331 | ||||
| 2025-12-15 | 13G/A | CRBP / Corbus Pharmaceuticals Holdings, Inc. | 2,375,000 | 2,344,971 | ||||
| 2025-12-08 | 13G/A | EYPT / EyePoint, Inc. | 8,325,000 | 8,265,000 | ||||
| 2025-11-14 | 13G/A | CRBP / Corbus Pharmaceuticals Holdings, Inc. | 2,375,000 | 2,375,000 | ||||
| 2025-11-14 | 13G/A | CABA / Cabaletta Bio, Inc. | 5,000,000 | 9,591,983 | ||||
| 2025-11-14 | 13G/A | RAPP / Rapport Therapeutics, Inc. | 2,940,921 | 3,192,521 | ||||
| 2025-11-14 | 13G/A | VYNE / VYNE Therapeutics Inc. | 1,370,938 | 0 | ||||
| 2025-11-14 | 13G/A | KALA / KALA BIO, Inc. | 609,027 | 0 | ||||
| 2025-11-14 | 13G/A | PRAX / Praxis Precision Medicines, Inc. | 1,625,000 | 1,000,000 | ||||
| 2025-11-14 | 13G | IBIO / iBio, Inc. | 2,248,010 | |||||
| 2025-08-14 | 13G/A | VYNE / VYNE Therapeutics Inc. | 1,849,590 | 1,370,938 | ||||
| 2025-08-14 | 13G/A | PRAX / Praxis Precision Medicines, Inc. | 1,745,000 | 1,625,000 | ||||
| 2025-08-14 | 13G | CABA / Cabaletta Bio, Inc. | 0 | 5,000,000 | ||||
| 2025-08-14 | 13G/A | BIOA / BioAge Labs, Inc. | 2,629,529 | 2,140,605 | ||||
| 2025-05-19 | 13G/A | VYNE / VYNE Therapeutics Inc. | 0 | 1,849,590 | ||||
| 2025-05-19 | 13G/A | OKUR / OnKure Therapeutics, Inc. | 1,837,739 | 0 | ||||
| 2025-05-15 | 13G/A | VYNE / VYNE Therapeutics Inc. | 1,394,336 | 0 | ||||
| 2025-05-15 | 13G/A | PRAX / Praxis Precision Medicines, Inc. | 1,693,219 | 1,745,000 | ||||
| 2025-05-15 | 13G | CRGX / CARGO Therapeutics, Inc. | 3,381,277 | |||||
| 2025-02-14 | 13G/A | PRAX / Praxis Precision Medicines, Inc. | 870,000 | 1,693,219 | ||||
| 2025-02-14 | 13G | KALA / KALA BIO, Inc. | 609,027 | |||||
| 2025-02-14 | 13G | BIOA / BioAge Labs, Inc. | 2,629,529 | |||||
| 2024-11-14 | 13G/A | RAPP / Rapport Therapeutics, Inc. | 2,940,283 | 2,940,921 | ||||
| 2024-11-14 | 13G/A | EYPT / EyePoint, Inc. | 6,038,235 | 8,325,000 | ||||
| 2024-11-14 | 13G/A | LBPH / Longboard Pharmaceuticals, Inc. | 2,141,506 | 2,790,462 | ||||
| 2024-11-14 | 13G/A | CRBP / Corbus Pharmaceuticals Holdings, Inc. | 2,025,000 | 2,375,000 | ||||
| 2024-11-14 | 13G/A | PRAX / Praxis Precision Medicines, Inc. | 633,345 | 870,000 | ||||
| 2024-11-14 | 13G/A | VTYX / Ventyx Biosciences, Inc. | 3,670,000 | 0 | ||||
| 2024-11-14 | 13G/A | TARS / Tarsus Pharmaceuticals, Inc. | 2,221,422 | 500,000 | ||||
| 2024-11-14 | 13G/A | TCRX / TScan Therapeutics, Inc. | 2,500,000 | 0 | ||||
| 2024-11-14 | 13G/A | MRNS / Marinus Pharmaceuticals, Inc. | 3,250,000 | 0 | ||||
| 2024-11-14 | 13G/A | NGNE / Neurogene Inc. | 746,180 | 107,344 | ||||
| 2024-11-14 | 13G/A | IMRX / Immuneering Corporation | 1,700,000 | 0 | ||||
| 2024-11-14 | 13G/A | KRRO / Korro Bio, Inc. | 529,170 | 265,826 | ||||
| 2024-11-14 | 13G/A | ALXO / ALX Oncology Holdings Inc. | 3,142,079 | 0 | ||||
| 2024-11-14 | 13G/A | CTMX / CytomX Therapeutics, Inc. | 5,750,000 | 0 | ||||
| 2024-11-06 | 13G/A | DRUG / Bright Minds Biosciences Inc. | 850,000 | 1,059,331 | ||||
| 2024-10-22 | 13G | DRUG / Bright Minds Biosciences Inc. | 850,000 | |||||
| 2024-10-16 | 13G/A | OKUR / OnKure Therapeutics, Inc. | 1,837,739 | |||||
| 2024-10-11 | 13G | OKUR / OnKure Therapeutics, Inc. | 1,895,717 | |||||
| 2024-06-20 | 13G | RAPP / Rapport Therapeutics, Inc. | 2,940,283 | |||||
| 2024-05-13 | 13G | CTMX / CytomX Therapeutics, Inc. | 5,750,000 | |||||
| 2024-04-29 | 13G | TCRX / TScan Therapeutics, Inc. | 2,500,000 | |||||
| 2024-04-15 | 13G/A | IMRX / Immuneering Corporation | 4,204,364 | 1,700,000 | ||||
| 2024-03-21 | 13G | VTYX / Ventyx Biosciences, Inc. | 3,670,000 | |||||
| 2024-03-18 | 13G/A | CRBP / Corbus Pharmaceuticals Holdings, Inc. | 0 | 2,025,000 | ||||
| 2024-02-14 | 13G/A | ALPN / Alpine Immune Sciences, Inc. | 2,850,000 | 2,550,000 | ||||
| 2024-02-14 | 13G/A | OLMA / Olema Pharmaceuticals, Inc. | 2,082,000 | 2,456,800 | ||||
| 2024-02-14 | 13G/A | AVTE / Aerovate Therapeutics, Inc. | 1,957,132 | 1,211,696 | ||||
| 2024-02-14 | 13G | NGNE / Neurogene Inc. | 746,180 | |||||
| 2024-02-14 | 13G/A | MRNS / Marinus Pharmaceuticals, Inc. | 2,800,000 | 3,250,000 | ||||
| 2024-02-14 | 13G/A | TARS / Tarsus Pharmaceuticals, Inc. | 1,736,422 | 2,221,422 | ||||
| 2024-02-14 | 13G/A | PRAX / Praxis Precision Medicines, Inc. | 633,345 | |||||
| 2024-02-14 | 13G/A | LBPH / Longboard Pharmaceuticals, Inc. | 1,801,947 | 2,141,506 | ||||
| 2024-02-14 | 13G/A | AMAM / Ambrx Biopharma Inc. | 11,231,000 | |||||
| 2024-02-14 | 13G/A | KRRO / Korro Bio, Inc. | 679,170 | 529,170 | ||||
| 2024-02-14 | 13G/A | GLUE / Monte Rosa Therapeutics, Inc. | 2,893,717 | 0 | ||||
| 2024-02-14 | 13G/A | DSGN / Design Therapeutics, Inc. | 5,150,000 | 0 | ||||
| 2024-02-14 | 13G/A | ELDN / Eledon Pharmaceuticals, Inc. | 1,391,663 | 0 | ||||
| 2024-02-14 | 13G/A | ELEV / Elevation Oncology, Inc. | 1,952,032 | 0 | ||||
| 2024-02-14 | 13G/A | CABA / Cabaletta Bio, Inc. | 1,971,739 | 0 | ||||
| 2024-02-14 | 13G/A | ETNB / 89bio, Inc. | 2,550,000 | 0 | ||||
| 2024-02-14 | 13G/A | ATXS / Astria Therapeutics, Inc. | 1,650,000 | 0 | ||||
| 2024-01-30 | 13D/A | ERAS / Erasca, Inc. | 10,893,107 | 0 | ||||
| 2023-12-14 | 13G/A | EYPT / EyePoint, Inc. | 6,038,235 | |||||
| 2023-11-16 | 13G | KRRO / Korro Bio, Inc. | 679,170 | |||||
| 2023-11-13 | 13G | VYNE / VYNE Therapeutics Inc. | 1,394,336 | |||||
| 2023-11-06 | 13G | HARP / Harpoon Therapeutics, Inc. | 1,678,619 | |||||
| 2023-10-23 | 13G | ALPN / Alpine Immune Sciences, Inc. | 2,850,000 | |||||
| 2023-10-13 | 13G | ALXO / ALX Oncology Holdings Inc. | 3,142,079 | |||||
| 2023-10-10 | 13G | MRNS / Marinus Pharmaceuticals, Inc. | 2,800,000 | |||||
| 2023-04-24 | 13G/A | IMRX / Immuneering Corporation | 2,286,181 | 4,204,364 | ||||
| 2023-03-13 | 13G/A | AMAM / Ambrx Biopharma Inc. | 16,354,702 | 52,500,000 | ||||
| 2023-02-14 | 13G/A | ELEV / Elevation Oncology, Inc. | 1,983,168 | 1,952,032 | ||||
| 2023-02-14 | 13G/A | DSGN / Design Therapeutics, Inc. | 5,440,451 | 5,150,000 | ||||
| 2023-02-14 | 13G/A | US39536G1058 / GREENLIGHT BIOSCIENCES HOLDINGS PBC A | 9,479,058 | 9,188,659 | ||||
| 2023-02-14 | 13G/A | IMRX / Immuneering Corporation | 2,252,628 | 2,286,181 | ||||
| 2023-02-14 | 13G/A | BCAB / BioAtla, Inc. | 2,038,215 | 3,680,365 | ||||
| 2023-02-14 | 13G/A | GLUE / Monte Rosa Therapeutics, Inc. | 3,002,200 | 2,893,717 | ||||
| 2023-02-14 | 13G/A | AMAM / Ambrx Biopharma Inc. | 17,266,144 | 16,354,702 | ||||
| 2023-02-14 | 13G/A | AVTE / Aerovate Therapeutics, Inc. | 1,830,691 | 1,957,132 | ||||
| 2023-02-14 | 13G/A | ALT / Altimmune, Inc. | 2,650,000 | 2,600,000 | ||||
| 2023-02-14 | 13G/A | OLMA / Olema Pharmaceuticals, Inc. | 2,169,871 | 2,082,000 | ||||
| 2023-02-14 | 13G/A | ACLX / Arcellx, Inc. | 2,200,000 | 2,075,000 | ||||
| 2023-02-14 | 13G/A | CABA / Cabaletta Bio, Inc. | 2,000,000 | 1,971,739 | ||||
| 2023-02-14 | 13G/A | LBPH / Longboard Pharmaceuticals, Inc. | 1,381,932 | 1,801,947 | ||||
| 2023-02-14 | 13G/A | VRDN / Viridian Therapeutics, Inc. | 1,436,322 | 1,100,000 | ||||
| 2023-02-14 | 13G/A | VECT / VectivBio Holding AG | 2,216,763 | 2,536,617 | ||||
| 2023-02-14 | 13G/A | ATXS / Astria Therapeutics, Inc. | 700,000 | 1,650,000 | ||||
| 2023-02-14 | 13G/A | TARS / Tarsus Pharmaceuticals, Inc. | 1,403,331 | 1,736,422 | ||||
| 2023-02-14 | 13G/A | RXDX / Prometheus Biosciences Inc | 2,224,847 | 2,090,000 | ||||
| 2023-02-14 | 13G/A | TNGX / Tango Therapeutics, Inc. | 4,899,184 | 4,116,949 | ||||
| 2023-02-14 | 13G/A | ELDN / Eledon Pharmaceuticals, Inc. | 1,428,598 | 1,391,663 | ||||
| 2022-12-29 | 13G | ETNB / 89bio, Inc. | 2,550,000 | |||||
| 2022-12-27 | 13G | RNA / Atrium Therapeutics, Inc. | 2,012,115 | 2,762,115 | ||||
| 2022-12-21 | 13D/A | ERAS / Erasca, Inc. | 10,505,553 | 10,893,107 | ||||
| 2022-10-31 | 13G | CABA / Cabaletta Bio, Inc. | 1,154,424 | 2,000,000 | ||||
| 2022-09-02 | 13G | ATXS / Astria Therapeutics, Inc. | 700,000 | |||||
| 2022-08-29 | 13G | ACLX / Arcellx, Inc. | 2,200,000 | |||||
| 2022-07-07 | 13G | ALT / Altimmune, Inc. | 2,650,000 | |||||
| 2022-06-17 | 13G | VECT / VectivBio Holding AG | 2,216,763 | |||||
| 2022-06-07 | 13G | RXDX / Prometheus Biosciences Inc | 1,848,022 | 2,224,847 | ||||
| 2022-02-14 | 13G | US39536G1058 / GREENLIGHT BIOSCIENCES HOLDINGS PBC A | 9,479,058 | |||||
| 2022-02-14 | 13G | TNGX / Tango Therapeutics, Inc. | 4,899,184 | |||||
| 2022-02-14 | 13G/A | RXDX / Prometheus Biosciences Inc | 1,848,022 | |||||
| 2022-02-14 | 13G/A | LBPH / Longboard Pharmaceuticals, Inc. | 1,339,631 | 1,381,932 | ||||
| 2022-02-14 | 13G/A | GLTO / Damora Therapeutics, Inc. | 2,150,732 | 1,020,240 | ||||
| 2022-02-14 | 13G/A | FMTX / Forma Therapeutics Holdings Inc | 4,460,000 | 4,639,998 | ||||
| 2022-02-14 | 13G/A | CCCC / C4 Therapeutics, Inc. | 2,490,065 | 0 | ||||
| 2022-02-14 | 13G/A | CABA / Cabaletta Bio, Inc. | 1,904,424 | 1,154,424 | ||||
| 2022-02-14 | 13G/A | RVMD / Revolution Medicines, Inc. | 3,675,000 | 2,431,852 | ||||
| 2022-02-14 | 13G/A | AVTE / Aerovate Therapeutics, Inc. | 2,030,691 | 1,830,691 | ||||
| 2022-02-14 | 13G/A | GLUE / Monte Rosa Therapeutics, Inc. | 3,193,974 | 3,002,200 | ||||
| 2022-02-14 | 13G/A | AMAM / Ambrx Biopharma Inc. | 17,404,702 | 17,266,144 | ||||
| 2022-02-14 | 13G/A | BCAB / BioAtla, Inc. | 2,292,060 | 2,038,215 | ||||
| 2022-02-14 | 13G/A | DSGN / Design Therapeutics, Inc. | 5,114,844 | 5,440,451 | ||||
| 2022-02-14 | 13G/A | RNA / Atrium Therapeutics, Inc. | 2,464,547 | 2,012,115 | ||||
| 2022-02-14 | 13G/A | VRDN / Viridian Therapeutics, Inc. | 459,144 | 1,436,322 | ||||
| 2022-02-14 | 13G/A | AVIR / Atea Pharmaceuticals, Inc. | 6,411,355 | 1,679,442 | ||||
| 2022-02-14 | 13G/A | OTIC / Otonomy Inc | 2,600,000 | 0 | ||||
| 2022-02-14 | 13G | TPTX / Turning Point Therapeutics Inc | 2,392,297 | 3,025,000 | ||||
| 2022-02-14 | 13G/A | OMER / Omeros Corporation | 5,000,000 | 0 | ||||
| 2022-02-14 | 13G/A | TARS / Tarsus Pharmaceuticals, Inc. | 1,714,269 | 1,403,331 | ||||
| 2022-02-14 | 13G/A | OLMA / Olema Pharmaceuticals, Inc. | 3,195,544 | 2,169,871 | ||||
| 2022-02-14 | 13G/A | ELDN / Eledon Pharmaceuticals, Inc. | 1,428,598 | |||||
| 2021-08-13 | 13G | IMRX / Immuneering Corporation | 2,252,628 | |||||
| 2021-08-10 | 13D/A | ERAS / Erasca, Inc. | 10,505,553 | 10,505,553 | ||||
| 2021-07-30 | 13D | ERAS / Erasca, Inc. | 10,505,553 | |||||
| 2021-07-12 | 13G | AVTE / Aerovate Therapeutics, Inc. | 2,030,691 | |||||
| 2021-07-09 | 13G | ELEV / Elevation Oncology, Inc. | 1,983,168 | |||||
| 2021-07-08 | 13G | GLUE / Monte Rosa Therapeutics, Inc. | 3,193,974 | |||||
| 2021-07-02 | 13G | AMAM / Ambrx Biopharma Inc. | 17,404,702 | |||||
| 2021-05-19 | 13G | RVMD / Revolution Medicines, Inc. | 2,495,066 | 3,675,000 | ||||
| 2021-04-09 | 13G | DSGN / Design Therapeutics, Inc. | 0 | 5,114,844 | ||||
| 2021-03-26 | 13G | LBPH / Longboard Pharmaceuticals, Inc. | 1,339,631 | |||||
| 2021-02-16 | 13G/A | CCXI / Churchill Capital Corp XI | 3,150,000 | 1,200,000 | ||||
| 2021-02-16 | 13G/A | US74257L1089 / Principia Biopharma Inc. | 1,990,922 | 0 | ||||
| 2021-02-16 | 13G/A | TPTX / Turning Point Therapeutics Inc | 3,396,650 | 2,392,297 | ||||
| 2021-02-16 | 13G/A | AVIR / Atea Pharmaceuticals, Inc. | 6,411,355 | |||||
| 2021-02-16 | 13G/A | TARS / Tarsus Pharmaceuticals, Inc. | 1,964,268 | 1,714,269 | ||||
| 2021-02-16 | 13G/A | GLTO / Damora Therapeutics, Inc. | 2,281,220 | 2,150,732 | ||||
| 2021-02-16 | 13G/A | OLMA / Olema Pharmaceuticals, Inc. | 3,270,544 | 3,195,544 | ||||
| 2021-02-16 | 13G/A | BCAB / BioAtla, Inc. | 2,292,060 | 2,292,060 | ||||
| 2021-02-16 | 13G/A | STOK / Stoke Therapeutics, Inc. | 1,788,663 | 1,437,807 | ||||
| 2021-02-16 | 13G/A | CABA / Cabaletta Bio, Inc. | 2,119,133 | 1,904,424 | ||||
| 2021-02-16 | 13G/A | US2103731061 / Constellation Pharmaceuticals Inc | 2,300,000 | 0 | ||||
| 2021-02-16 | 13G/A | ARCT / Arcturus Therapeutics Holdings Inc. | 1,144,537 | 0 | ||||
| 2021-02-16 | 13G/A | RNA / Atrium Therapeutics, Inc. | 2,514,545 | 2,464,547 | ||||
| 2021-02-16 | 13G/A | OMER / Omeros Corporation | 3,000,000 | 5,000,000 | ||||
| 2021-02-16 | 13G/A | FMTX / Forma Therapeutics Holdings Inc | 3,379,370 | 4,460,000 | ||||
| 2021-02-16 | 13G/A | AVEO / AVEO Pharmaceuticals Inc | 1,350,000 | 0 | ||||
| 2021-02-16 | 13G/A | CCCC / C4 Therapeutics, Inc. | 2,490,068 | 2,490,065 | ||||
| 2021-02-16 | 13G/A | OTIC / Otonomy Inc | 2,500,000 | 2,600,000 | ||||
| 2021-02-16 | 13G/A | AGEN / Agenus Inc. | 11,500,000 | 7,000,000 | ||||
| 2021-02-16 | 13G/A | RVMD / Revolution Medicines, Inc. | 3,245,177 | 2,495,066 | ||||
| 2021-01-19 | 13G | VRDN / Viridian Therapeutics, Inc. | 459,144 | |||||
| 2021-01-19 | 13G | VRDN / Viridian Therapeutics, Inc. | 459,144 | |||||
| 2021-01-04 | 13G | 88907J107 / Novus Therapeutics, Inc. | 1,415,500 | |||||
| 2020-12-28 | 13G | BCAB / BioAtla, Inc. | 2,292,060 | |||||
| 2020-11-23 | 13G | OLMA / Olema Pharmaceuticals, Inc. | 3,270,544 | |||||
| 2020-11-12 | 13G | GLTO / Damora Therapeutics, Inc. | 2,281,220 | |||||
| 2020-10-30 | 13G | TARS / Tarsus Pharmaceuticals, Inc. | 1,964,268 | |||||
| 2020-10-16 | 13G | CCCC / C4 Therapeutics, Inc. | 2,490,068 | |||||
| 2020-07-20 | 13G | OTIC / Otonomy Inc | 2,500,000 | |||||
| 2020-07-06 | 13G | FMTX / Forma Therapeutics Holdings Inc | 3,379,370 | |||||
| 2020-06-29 | 13G | AVEO / AVEO Pharmaceuticals Inc | 1,350,000 | |||||
| 2020-06-26 | 13G | RNA / Atrium Therapeutics, Inc. | 2,514,545 | |||||
| 2020-05-04 | 13G | OMER / Omeros Corporation | 900,000 | 3,000,000 | ||||
| 2020-04-27 | 13G | ARCT / Arcturus Therapeutics Holdings Inc. | 1,144,537 | |||||
| 2020-03-20 | 13G | AGEN / Agenus Inc. | 11,500,000 | |||||
| 2020-02-24 | 13G | RVMD / Revolution Medicines, Inc. | 3,245,177 | |||||
| 2020-02-14 | 13G/A | US74257L1089 / Principia Biopharma Inc. | 1,474,362 | 1,990,922 | ||||
| 2020-02-14 | 13G/A | US2103731061 / Constellation Pharmaceuticals Inc | 1,747,776 | 2,300,000 | ||||
| 2020-02-14 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 2,150,000 | 1,782,392 | ||||
| 2020-02-14 | 13G/A | TPTX / Turning Point Therapeutics Inc | 3,122,367 | 3,396,650 | ||||
| 2020-02-14 | 13G/A | IFRX / InflaRx N.V. | 2,670,000 | 0 | ||||
| 2020-02-14 | 13G/A | AVRO / AVROBIO, Inc. | 1,357,784 | 317,579 | ||||
| 2020-02-14 | 13G/A | KZR / Kezar Life Sciences, Inc. | 1,422,911 | 0 | ||||
| 2020-02-14 | 13G/A | QTNT / Quotient Ltd | 4,762,772 | 3,500,000 | ||||
| 2020-02-14 | 13G/A | IMVT / Immunovant, Inc. | 1,080,000 | |||||
| 2020-02-14 | 13G/A | NXTC / NextCure, Inc. | 1,200,000 | 1,000,000 | ||||
| 2020-02-14 | 13G/A | CABA / Cabaletta Bio, Inc. | 2,119,132 | 2,119,133 | ||||
| 2020-02-14 | 13G/A | DRNA / Dicerna Pharmaceuticals Inc | 3,481,471 | 0 | ||||
| 2020-02-14 | 13G/A | STOK / Stoke Therapeutics, Inc. | 1,869,680 | 1,788,663 | ||||
| 2020-02-14 | 13G/A | XFOR / X4 Pharmaceuticals, Inc. | 940,387 | 488,565 | ||||
| 2020-02-14 | 13G/A | APLS / Apellis Pharmaceuticals, Inc. | 4,502,498 | 2,700,000 | ||||
| 2020-01-10 | 13G | CCXI / Churchill Capital Corp XI | 3,300,000 | 3,150,000 | ||||
| 2019-12-16 | 13G | CCXI / Churchill Capital Corp XI | 3,300,000 | |||||
| 2019-11-18 | 13G | NXTC / NextCure, Inc. | 1,200,000 | |||||
| 2019-11-18 | 13G | US2103731061 / Constellation Pharmaceuticals Inc | 1,271,687 | 1,747,776 | ||||
| 2019-11-14 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 1,751,699 | 2,150,000 | ||||
| 2019-11-07 | 13G | CABA / Cabaletta Bio, Inc. | 2,119,132 | |||||
| 2019-07-01 | 13G | STOK / Stoke Therapeutics, Inc. | 1,869,680 | |||||
| 2019-05-20 | 13G | IMVT / Immunovant, Inc. | 1,080,000 | |||||
| 2019-05-20 | 13G | IMVT / Immunovant, Inc. | 1,080,000 | |||||
| 2019-05-03 | 13G | EIGR / Eiger BioPharmaceuticals, Inc. | 1,300,000 | |||||
| 2019-04-25 | 13G | TPTX / Turning Point Therapeutics Inc | 3,122,367 | |||||
| 2019-04-22 | 13G/A | IFRX / InflaRx N.V. | 1,475,140 | 2,670,000 | ||||
| 2019-04-22 | 13G | XFOR / X4 Pharmaceuticals, Inc. | 940,387 | |||||
| 2019-02-14 | 13G/A | AVRO / AVROBIO, Inc. | 1,507,781 | 1,357,784 | ||||
| 2019-02-14 | 13G/A | IFRX / InflaRx N.V. | 1,438,207 | 1,475,140 | ||||
| 2019-02-14 | 13G/A | GEMP / Gemphire Therapeutics Inc. | 839,599 | 39,599 | ||||
| 2019-02-14 | 13G/A | QTNT / Quotient Ltd | 4,587,683 | 4,762,772 | ||||
| 2019-02-14 | 13G/A | TRIL / Tidal Trust II - Defiance Trillion Dollar Club Index ETF | 600,000 | 0 | ||||
| 2019-02-14 | 13G/A | IL0011177958 / Intec Pharma Ltd | 809,804 | 0 | ||||
| 2019-02-14 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 1,430,600 | 1,751,699 | ||||
| 2019-02-14 | 13G/A | CLSD / Clearside Biomedical, Inc. | 1,940,880 | 0 | ||||
| 2019-02-14 | 13G/A | US74257L1089 / Principia Biopharma Inc. | 1,486,898 | 1,474,362 | ||||
| 2019-02-14 | 13G/A | APLS / Apellis Pharmaceuticals, Inc. | 3,768,756 | 4,502,498 | ||||
| 2019-02-14 | 13G/A | CFRX / ContraFect Corp | 6,668,203 | 6,023,841 | ||||
| 2019-02-14 | 13G/A | YMTX / Yumanity Therapeutics Inc | 3,300,000 | 0 | ||||
| 2019-02-14 | 13G/A | DRNA / Dicerna Pharmaceuticals Inc | 3,656,669 | 3,481,471 | ||||
| 2019-02-14 | 13G/A | ANAB / AnaptysBio, Inc. | 1,254,185 | 1,105,557 | ||||
| 2019-02-14 | 13G/A | KZR / Kezar Life Sciences, Inc. | 1,572,909 | 1,422,911 | ||||
| 2019-02-14 | 13G/A | US2103731061 / Constellation Pharmaceuticals Inc | 1,471,687 | 1,271,687 | ||||
| 2019-02-14 | 13G/A | KNSA / Kiniksa Pharmaceuticals International, plc | 830,999 | 831,000 | ||||
| 2018-11-09 | 13G | AXNX / Axonics, Inc. | 1,285,827 | |||||
| 2018-09-24 | 13G | US74257L1089 / Principia Biopharma Inc. | 1,486,898 | |||||
| 2018-07-30 | 13G | US2103731061 / Constellation Pharmaceuticals Inc | 1,471,687 | |||||
| 2018-07-02 | 13G | AVRO / AVROBIO, Inc. | 1,507,781 | |||||
| 2018-07-02 | 13G | KZR / Kezar Life Sciences, Inc. | 1,572,909 | |||||
| 2018-06-04 | 13G | KNSA / Kiniksa Pharmaceuticals International, plc | 830,999 | |||||
| 2018-02-14 | 13G | IFRX / InflaRx N.V. | 1,438,207 | |||||
| 2018-02-14 | 13G/A | QTNT / Quotient Ltd | 2,940,000 | 4,587,683 | ||||
| 2018-02-14 | 13G/A | GEMP / Gemphire Therapeutics Inc. | 900,000 | 839,599 | ||||
| 2018-02-14 | 13G/A | CRBP / Corbus Pharmaceuticals Holdings, Inc. | 2,500,000 | 0 | ||||
| 2018-02-14 | 13G/A | ZYNE / Zynerba Pharmaceuticals Inc | 480,501 | 0 | ||||
| 2018-02-14 | 13G/A | NERV / Minerva Neurosciences, Inc. | 2,652,436 | 607,903 | ||||
| 2018-02-14 | 13G/A | APTO / Aptose Biosciences Inc. | 990,579 | 0 | ||||
| 2018-02-14 | 13G/A | TGXSF / Tigenix Sa | 14,472,631 | 9,972,386 | ||||
| 2018-02-14 | 13G/A | 451731103 / Ignyta, Inc. | 3,000,000 | 0 | ||||
| 2018-02-14 | 13G/A | CLSD / Clearside Biomedical, Inc. | 2,333,333 | 1,940,880 | ||||
| 2018-02-14 | 13G/A | APLS / Apellis Pharmaceuticals, Inc. | 3,768,756 | |||||
| 2018-02-14 | 13G/A | CFRX / ContraFect Corp | 4,188,212 | 6,668,203 | ||||
| 2018-02-14 | 13G/A | DRNA / Dicerna Pharmaceuticals Inc | 2,307,898 | 3,656,669 | ||||
| 2018-02-14 | 13G/A | ANAB / AnaptysBio, Inc. | 1,168,394 | 1,254,185 | ||||
| 2018-02-14 | 13G/A | OMER / Omeros Corporation | 975,000 | 900,000 | ||||
| 2018-01-22 | 13G | MRTX / Mirati Therapeutics, Inc. | 1,430,600 | |||||
| 2017-12-18 | 13G/A | YMTX / Yumanity Therapeutics Inc | 3,804,027 | 3,300,000 | ||||
| 2017-11-21 | 13G | APLS / Apellis Pharmaceuticals, Inc. | 3,473,925 | |||||
| 2017-10-20 | 13G | ANAB / AnaptysBio, Inc. | 1,168,394 | |||||
| 2017-09-11 | 13G | 451731103 / Ignyta, Inc. | 3,000,000 | |||||
| 2017-06-05 | 13G | TRIL / Tidal Trust II - Defiance Trillion Dollar Club Index ETF | 600,000 | |||||
| 2017-04-21 | 13G | DRNA / Dicerna Pharmaceuticals Inc | 2,307,898 | |||||
| 2017-02-14 | 13G/A | APTO / Aptose Biosciences Inc. | 990,579 | |||||
| 2017-02-14 | 13G/A | VTAE / Vitae Pharmaceuticals, Inc. | 0 | |||||
| 2017-02-14 | 13G | TGXSF / Tigenix Sa | 14,601,663 | 14,472,631 | ||||
| 2017-02-14 | 13G/A | ZYNE / Zynerba Pharmaceuticals Inc | 780,501 | 480,501 | ||||
| 2017-02-14 | 13G/A | REPH / Societal CDMO Inc | 603,000 | |||||
| 2017-02-14 | 13G/A | YMTX / Yumanity Therapeutics Inc | 2,450,882 | 3,804,027 | ||||
| 2017-02-14 | 13G/A | QTNT / Quotient Ltd | 2,940,000 | |||||
| 2017-02-14 | 13G/A | SRNE / Sorrento Therapeutics, Inc. | 1,909,000 | |||||
| 2017-02-14 | 13G/A | VIRX / Viracta Therapeutics, Inc. | 1,000,000 | 1,000,000 | ||||
| 2017-02-14 | 13G/A | OMER / Omeros Corporation | 975,000 | |||||
| 2017-02-14 | 13G/A | US62857M1053 / MyoKardia, Inc. | 1,605,790 | 1,445,090 | ||||
| 2017-02-14 | 13G/A | IL0011177958 / Intec Pharma Ltd | 809,804 | |||||
| 2017-02-14 | 13G/A | NERV / Minerva Neurosciences, Inc. | 2,652,436 | |||||
| 2017-02-14 | 13G/A | CRBP / Corbus Pharmaceuticals Holdings, Inc. | 2,350,700 | 2,500,000 | ||||
| 2017-02-14 | 13G/A | GNVC / GenVec, Inc. | 0 | |||||
| 2017-02-14 | 13G/A | CLSD / Clearside Biomedical, Inc. | 1,988,208 | 2,333,333 | ||||
| 2017-02-14 | 13G/A | CFRX / ContraFect Corp | 4,255,576 | 4,188,212 | ||||
| 2017-02-14 | 13G/A | CLRB / Cellectar Biosciences, Inc. | 106,648 | |||||
| 2017-02-14 | 13G/A | ARDX / Ardelyx, Inc. | 2,212,151 | |||||
| 2017-01-30 | 13G | ZYNE / Zynerba Pharmaceuticals Inc | 780,501 | |||||
| 2016-12-23 | 13G | TGXSF / Tigenix Sa | 14,601,663 | |||||
| 2016-11-07 | 13G/A | YMTX / Yumanity Therapeutics Inc | 2,450,882 | |||||
| 2016-10-31 | 13G | VIRX / Viracta Therapeutics, Inc. | 1,000,000 | |||||
| 2016-10-11 | 13G | US62857M1053 / MyoKardia, Inc. | 1,605,790 | |||||
| 2016-09-29 | 13G | CRBP / Corbus Pharmaceuticals Holdings, Inc. | 2,350,700 | |||||
| 2016-08-15 | 13G | GEMP / Gemphire Therapeutics Inc. | 900,000 | |||||
| 2016-08-01 | 13G | CFRX / ContraFect Corp | 4,255,576 | |||||
| 2016-06-13 | 13G | CLSD / Clearside Biomedical, Inc. | 1,988,208 | |||||
| 2014-09-02 | 13G | CLRB / Cellectar Biosciences, Inc. | 1,060,000 | |||||
| 2014-04-14 | 13G | APTO / Aptose Biosciences Inc. | 13,000,000 | |||||
| 2014-03-25 | 13G | GNVC / GenVec, Inc. | 1,329,300 | |||||
| 2014-03-17 | 13G | REPH / Societal CDMO Inc | 500,000 |
